Amneal Pharmaceuticals, Inc. (AMRX): Price and Financial Metrics
AMRX Price/Volume Stats
| Current price | $5.90 | 52-week high | $6.30 |
| Prev. close | $5.89 | 52-week low | $1.24 |
| Day low | $5.74 | Volume | 1,154,700 |
| Day high | $5.93 | Avg. volume | 1,337,815 |
| 50-day MA | $5.50 | Dividend yield | N/A |
| 200-day MA | $3.99 | Market Cap | 1.81B |
AMRX Stock Price Chart Interactive Chart >
AMRX POWR Grades
- AMRX scores best on the Value dimension, with a Value rank ahead of 99.73% of US stocks.
- The strongest trend for AMRX is in Quality, which has been heading up over the past 168 days.
- AMRX's current lowest rank is in the Momentum metric (where it is better than 7.06% of US stocks).
AMRX Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for AMRX is 7.21 -- better than 94.49% of US stocks.
- With a price/earnings ratio of 174.01, AMNEAL PHARMACEUTICALS INC P/E ratio is greater than that of about 96.67% of stocks in our set with positive earnings.
- In terms of twelve month growth in earnings before interest and taxes, AMNEAL PHARMACEUTICALS INC is reporting a growth rate of 693.06%; that's higher than 98.31% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to AMNEAL PHARMACEUTICALS INC are ESMT, PODD, CLPS, UPWK, and PAY.
- Visit AMRX's SEC page to see the company's official filings. To visit the company's web site, go to www.amneal.com.
AMRX Valuation Summary
- AMRX's price/earnings ratio is 180.2; this is 518.18% higher than that of the median Healthcare stock.
- AMRX's price/sales ratio has moved down 4.9 over the prior 70 months.
Below are key valuation metrics over time for AMRX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| AMRX | 2023-12-29 | 0.8 | 5.6 | 180.2 | 22.3 |
| AMRX | 2023-12-28 | 0.8 | 5.7 | 181.7 | 22.3 |
| AMRX | 2023-12-27 | 0.8 | 5.8 | 184.4 | 22.5 |
| AMRX | 2023-12-26 | 0.8 | 5.4 | 174.3 | 22.0 |
| AMRX | 2023-12-22 | 0.7 | 5.3 | 171.0 | 21.8 |
| AMRX | 2023-12-21 | 0.7 | 5.1 | 164.5 | 21.5 |
AMRX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AMRX has a Quality Grade of C, ranking ahead of 25.42% of graded US stocks.
- AMRX's asset turnover comes in at 0.514 -- ranking 77th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows AMRX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.514 | 0.343 | 0.037 |
| 2021-03-31 | 0.495 | 0.320 | 0.031 |
| 2020-12-31 | 0.483 | 0.315 | 0.032 |
| 2020-09-30 | 0.466 | 0.304 | 0.028 |
| 2020-06-30 | 0.440 | 0.283 | 0.063 |
| 2020-03-31 | 0.419 | 0.270 | 0.060 |
Amneal Pharmaceuticals, Inc. (AMRX) Company Bio
Amneal Pharmaceuticals (formerly Impax Laboratories) develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The company was founded in 1993 and is based in Hayward, California.
Latest AMRX News From Around the Web
Below are the latest news stories about AMNEAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AMRX as an investment opportunity.
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceBRIDGEWATER, N.J., December 21, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. Chirag will present on January 10th at 11:15 AM PST, and a live webcast will be accessible on the Company's website at https://investors.amneal.com. A replay of the webcast will be available for 30 days f |
Amneal Announces Move to NasdaqBRIDGEWATER, N.J., December 15, 2023--Amneal Pharmaceuticals, Inc. ("Amneal") (NYSE: AMRX) today announced that it will transfer its stock exchange listing to the Nasdaq Stock Market ("Nasdaq") from the New York Stock Exchange ("NYSE"). The Company expects the Nasdaq listing to occur on December 27, 2023 and will continue to trade under the current symbol "AMRX". Upon transferring, Amneal will become part of the Nasdaq Composite Index and Nasdaq Biotechnology Index. |
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)BRIDGEWATER, N.J. & PORTO, Portugal, December 07, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal") and BIAL - Portela & Ca., S.A. ("BIAL"), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023. Amneal expects to begin distribution of ONGENTYS® in early 2024. |
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel CapsulesBRIDGEWATER, N.J., December 01, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") and Strides Pharma Science Limited ("Strides") today announced the addition of Icosapent ethyl acid soft gel capsules, a product referencing VASCEPA®. The product has been in-licensed from Strides, a global pharmaceutical manufacturer, and will be commercialized by Amneal starting in the fourth quarter of 2023. |
Should You Be Excited About Amneal Pharmaceuticals, Inc.'s (NYSE:AMRX) 20% Return On Equity?One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will... |
AMRX Price Returns
| 1-mo | 9.26% |
| 3-mo | 31.99% |
| 6-mo | 44.25% |
| 1-year | 142.80% |
| 3-year | 4.80% |
| 5-year | -56.20% |
| YTD | -2.80% |
| 2023 | 205.03% |
| 2022 | -58.46% |
| 2021 | 4.81% |
| 2020 | -5.19% |
| 2019 | -64.38% |
Continue Researching AMRX
Here are a few links from around the web to help you further your research on Amneal Pharmaceuticals Inc's stock as an investment opportunity:Amneal Pharmaceuticals Inc (AMRX) Stock Price | Nasdaq
Amneal Pharmaceuticals Inc (AMRX) Stock Quote, History and News - Yahoo Finance
Amneal Pharmaceuticals Inc (AMRX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...